公开(公告)号：US10744197B2

公开(公告)日：2020-08-18

申请号：US15777396

申请日：2016-11-28

Applicant: NITTO DENKO CORPORATION

Inventor： Takuya Shishido ,  Daisuke Asari ,  Eiji Kiyotoh ,  Kyohei Matsushita ,  Wenjing Li ,  Masahiro Fukasaka ,  Katsuyuki Okubo ,  Mitsuhiko Hori

IPC: A61K39/00 ,  C07K14/00 ,  C12N9/90 ,  A61K38/00 ,  A61K39/108 ,  A61K39/145 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K9/19 ,  A61P31/16 ,  A61K47/18

Abstract: The present invention provides a vaccine pharmaceutical composition for oral administration that enables stable storage of an influenza virus antigen and a method for producing the pharmaceutical composition. Provided is a vaccine pharmaceutical composition for oral administration containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.

公开(公告)号：US10456464B2

公开(公告)日：2019-10-29

申请号：US15501339

申请日：2015-08-04

Applicant: NITTO DENKO CORPORATION

Inventor： Takuya Shishido ,  Daisuke Asari ,  Kyohei Matsushita ,  Mitsuhiko Hori

IPC: A61K39/39 ,  A61K31/235 ,  A61K31/4465 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/5377 ,  A61K39/00

Abstract: The present invention aims to provide a humoral immunity induction-promoting composition and a vaccine pharmaceutical composition which can universally be used for inducing humoral immunity to various antigens and exert a high antibody production inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing humoral immunity containing an antigen and a humoral immunity induction promoter whose active ingredient is a thrombosis treatment drug.

公开(公告)号：US10420837B2

公开(公告)日：2019-09-24

申请号：US15514868

申请日：2015-10-01

Applicant: NITTO DENKO CORPORATION

Inventor： Takuya Shishido ,  Daisuke Asari ,  Kyohei Matsushita ,  Katsuyuki Okubo ,  Mitsuhiko Hori

IPC: A61K39/39 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K9/70

Abstract: The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt, derived from at least one gram-negative bacterium such as Serratia, Lelercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant/the total mass of the antigen, of 0.002 to 500.